IntraVenous Immune Boost

Project Information

IVI-Boost

Grant agreement ID: 101145244

DOI 10.3030/101145244

EC signature date 9 February 2024

Start date 1 May 2024

End date 28 February 2026

Funded under

• The European Innovation Council (EIC)

Total cost € 6 910 955,50

EU contribution € 2 499 999,00

Coordinated by

HEPHAISTOS-PHARMA
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Conference proceedings (1)

A systemically administered innate immune modulator displays potent anti-tumor activity against metastatic osteosarcoma

Author(s): A. Nabeshima, R. Oyama, M. Endo, C. Phelip, I. Fajnorova, K. Chettab, A. Novikov, C. Dumontet, A. Dutour, M. Caroff, J. Kerzerho
Published in: ESMO sarcomas and rare cancers, 2025
Publisher: Annals of Oncology

Peer reviewed articles (1)

A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration

Author(s): Ryunosuke Oyama, Akira Nabeshima, Makoto Endo, Alexey Novikov, Toshifumi Fujiwara, Capucine Phelip, Nobuhiko Yokoyama, Yoshinao Oda, Martine Caroff, Yoshihiro Matsumoto, Jerome Kerzerho, Yasuharu Nakashima
Published in: BJC Reports, Issue 3, 2025, ISSN 2731-9377
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/s44276-024-00120-3

Intellectual Property Rights

Patent (2)

DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF

Application/Publication number: 20 21056428
Date: 2021-03-12
Applicant(s): HEPHAISTOS-PHARMA

LIPOSOMAL FORMULATION OF BACTERIAL LIPOPOLYSACCHARIDE COMBINED WITH A CYTOTOXIC AGENT, AND USE THEREOF IN ANTI-TUMOUR THERAPY

Application/Publication number: 18 811060
Date: 2018-10-30
Applicant(s): HEPHAISTOS-PHARMA